Hookipa Biotech AG, which is developing viral vectors that can invoke a strong immune response to cancer, has appointed Igor Matushansky as head of research and development. Dr Matushansky joins from Daiichi Sankyo where he led a research unit focused on early oncology programmes. Before that, he was global head for clinical and scientific development of cell and gene therapies at Novartis. Dr Matushansky received his MD as well as a PhD in molecular biology from the Albert Einstein College of Medicine in New York City.
Hookipa announced the appointment on 6 March 2017.
Copyright 2017 Evernow Publishing Ltd